Evidence map›Paper›PMID 30449885›Full record

ArticleBritish journal of cancer2018

Exploring the transcriptome of hormone-naive multifocal prostate cancer and matched lymph node metastases.

Linnéa Schmidt, Mia Møller, Christa Haldrup, Siri H Strand, Søren Vang, Jakob Hedegaard, Søren Høyer, Michael Borre, Torben Ørntoft, Karina Dalsgaard Sørensen

Open access · hybridAbstract read
In one paragraph

Article in British journal of cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.7field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Linnéa SchmidtDepartment of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark.
Mia MøllerDepartment of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark.
Christa HaldrupDepartment of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark.
Siri H StrandDepartment of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark.
Søren VangDepartment of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark.
Jakob HedegaardDepartment of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark.
Søren HøyerDepartment of Pathology, Aarhus University Hospital, Aarhus, Denmark.
Michael BorreDepartment of Urology, Aarhus University Hospital, Aarhus, Denmark.
Torben ØrntoftDepartment of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark.
Karina Dalsgaard SørensenDepartment of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark. kdso@clin.au.dk.
Aarhus University Hospital · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe current inability to predict whether a primary prostate cancer (PC) will progress to metastatic disease leads to overtreatment of indolent PCs as well as undertreatment of aggressive PCs. Here, we explored the transcriptional changes associated with metastatic progression of multifocal hormone-naive PC.

methodsUsing total RNA-sequencing, we analysed laser micro-dissected primary PC foci (n = 23), adjacent normal prostate tissue samples (n = 23) and lymph node metastases (n = 9) from ten hormone-naive PC patients. Genes important for PC progression were identified using differential gene expression and clustering analysis. From these, two multi-gene-based expression signatures (models) were developed, and their prognostic potential was evaluated using Cox-regression and Kaplan-Meier analyses in three independent radical prostatectomy (RP) cohorts (>650 patients).

resultsWe identified several novel PC-associated transcripts deregulated during PC progression, and these transcripts were used to develop two novel gene-expression-based prognostic models. The models showed independent prognostic potential in three RP cohorts (n = 405, n = 107 and n = 91), using biochemical recurrence after RP as the primary clinical endpoint.

conclusionsWe identified several transcripts deregulated during PC progression and developed two new prognostic models for PC risk stratification, each of which showed independent prognostic value beyond routine clinicopathological factors in three independent RP cohorts.

Indexed as

TranscriptomeAgedDisease ProgressionHumansLymphatic MetastasisMaleMiddle AgedPrognosisProstatic NeoplasmsSequence Analysis, RNA

Identifiers

PMID30449885
PMCPMC6288156
OpenAlexW2900854023

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.